BRAIN Biotech AG
ISIN: DE0005203947
WKN: 520394
20 September 2024 07:50PM

EQS-News: BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator

BRAIN Biotech AG · ISIN: DE0005203947 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1992785

EQS-News: BRAIN Biotech AG / Key word(s): Contract
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator

20.09.2024 / 19:50 CET/CEST
The issuer is solely responsible for the content of this announcement.


BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator

  • Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech
  • Immediate upfront payment of EUR 18.41 million
  • Royalty monetization of an investigational compound, deucrictibant, with market leading Royalty Pharma
  • Contractual milestone payments of up to EUR 9.0 million for the nearer-term clinical progress stay with BRAIN Biotech

 

Zwingenberg, Germany, 20 September 2024 – BRAIN Biotech AG (“Company”) concluded a royalty monetization deal on the royalty rights to an investigational compound, deucrictibant, with Royalty Pharma for up to EUR 128.88 million. The Company will receive an upfront payment of EUR 18.41 million, additional potential regulatory milestones of up to EUR 18.42 million and additional potential long-term sales related milestones of up to EUR 92.05 million.

Adriaan Moelker, CEO of BRAIN Biotech AG, states: "This is truly a milestone transaction in the history of BRAIN Biotech. We have always believed in the high value of our BioIncubator projects and are now starting to increasingly harvest the strong pipeline investments of the past. This transaction with market leader Royalty Pharma has not only confirmed our value assumptions of deucrictibant but also allowed us to significantly forward cash proceeds from this exciting project. With the proceeds we will accelerate the ongoing transformation of BRAIN Biotech to a global top ten player in the highly attractive market of industrial enzymes. We will continue to focus here on our core areas of Food, Beverage and Life Sciences with a very strong heritage in scientific excellence."

A result of the Company’s BioIncubator pipeline of highly innovative projects, deucrictibant is currently in clinical development by Pharvaris Netherlands NV (Nasdaq PHVS) for the treatment of Hereditary Angioedema. This project was initiated by group subsidiary AnalytiCon Discovery, which has been merged into the Company but will continue to work as an independent commercial unit of BRAIN Biotech AG. All existing commitments and licenses associated with the investigational compound will be transferred from BRAIN Biotech to Royalty Pharma. BRAIN Biotech intends to commercialize and monetize additional projects with high value from its BioIncubator pipeline during the next years.

Michael Schneiders, CFO of BRAIN Biotech AG, says: “Royalty monetization is a very interesting and innovative form of alternative non-dilutive financing for us in an environment of an ultra-low BRAIN Biotech share price. We have not only been able to raise significant immediate proceeds via the upfront payment but will also participate in the ongoing clinical success of the investigational compound by nearer term regulatory milestones and further long-term payments related to the potential sales development of deucrictibant. The value of this single transaction is more than four times the total market capitalization of BRAIN Biotech prior to the deal announcement.” Schneiders adds, “We are very confident that the strong operational and structural development which started in the last three years in conjunction with increasingly crystallizing value from our BioIncubator pipeline will bring BRAIN Biotech AG back to the agenda of equity investors. In this transaction we have only monetized the future royalties on deucrictibant. Additional contractual milestone payments of up to 9.0 million EUR for the nearer term clinical progress stay with BRAIN Biotech.”

The Company intends to use the net proceeds of this transaction to accelerate its ongoing transformation to a global top ten position in industrial enzymes, for future growth funding including potential M&A transactions and short-term loan repayments. This transaction remains subject to customary closing conditions.

+++

About BRAIN Biotech

BRAIN Biotech AG is a leading provider of integrated solutions and products in the field of industrial biotechnology. The company specializes in enzymes and proteins, microbial production strains and bioprocesses for biotechnological production methods. BRAIN Biotech focuses on the growth markets of nutrition and life sciences as well as on innovative solutions for environment issues. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. Its business activities are divided into three segments: 1. BioProducts: Production and sale of specialty enzymes and proteins; 2. BioScience: Customized solutions based on enzyme engineering, production strain and bioprocess development, and screening for bioactive compounds; 3. BioIncubator: Pipeline of research-intensive development projects. For production, the Group operates fermentation plants in the UK and other production facilities in continental Europe and the USA. BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 310 people and generated revenues of EUR 55.3 million in the fiscal year 2022/23. For more information, please visit www.brain-biotech-group.com

About AnalytiCon Discovery

AnalytiCon Discovery is an independent commercial unit of BRAIN Biotech AG with many years of R&D expertise in natural product chemistry. The Potsdam-based operation site specializes in small molecule compounds and offers customers from the pharmaceutical, cosmetics, food and agricultural sectors the development of substance libraries, the identification of active ingredients and their synthetic optimization as well as the production of active ingredients on a commercial scale. AnalytiCon has been part of the BRAIN Biotech Group since 2013. Further information: www.ac-discovery.com

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products. Further information: https://www.royaltypharma.com/

 

Contact Media BRAIN Biotech

Dr. Stephanie Konle

PR & Corporate Communications

Phone: +49 6251 9331-70

Email: stk@brain-biotech.com

 

Contact Investor Relations BRAIN Biotech

Martina Schuster

Investor Relations

Phone: +49 6251 9331-69

Email: ms@brain-biotech.com

 

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

 



20.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.com
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1992785

 
End of News EQS News Service

1992785  20.09.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1992785&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 27,05 38,56 38,23 38,39 45,51 55,34 65,00
EBITDA1,2 -6,55 -2,50 -3,88 -2,53 -1,31 -0,83 3,50
EBITDA-Margin3 -24,21 -6,48 -10,15 -6,59 -2,88 -1,50 5,39
EBIT1,4 -9,57 -7,20 -8,23 -6,55 -5,65 -5,48 0,00
EBIT-Margin5 -35,38 -18,67 -21,53 -17,06 -12,42 -9,90 0,00
Net Profit (Loss)1 -8,37 -11,12 -9,02 -4,68 -6,34 -8,11 -4,00
Net-Margin6 -30,94 -28,84 -23,59 -12,19 -13,93 -14,66 -6,15
Cashflow1,7 -5,42 -3,38 -4,77 -3,10 -1,49 -4,22 -1,50
Earnings per share8 -0,45 -0,61 -0,52 -0,25 -0,30 -0,38 -0,18
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Baker Tilly

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
BRAIN Biotech
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
520394 DE0005203947 AG 75,81 Mio € 09.02.2016 Halten 8FXCPJH6+57
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
34,70 0,00 0,00 -7,54 3,48 -17,97 1,37
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
18.03.2025 26.02.2025 28.05.2024 29.08.2024 15.01.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-1,70%
3,47 €
ATH 27,75 €
+17,47% +32,14% -5,19% -1,70% -61,44%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL